Sanofi to collaborate with Mass General on cancer drug development; Foundation Medicine inks development past with Eisai;

 @FierceBiotech: Fight against 'unwarranted' drug patents goes online. FierceBiotechIT article | Follow @FierceBiotech

 @JohnCFierce: Interesting. Twitter conclusion: Solanezumab a complete bust. But on BMBG, Reuters etc., it's an intriguing "win" for patients. Disconnect. | Follow @JohnCFierce

 @RyanMFierce: Magic Johnson is using his celebrity to bring attention to OraSure's at-home HIV test. A good use of his celebrity, I think.  | Follow @RyanMFierce

> Investigators from Sanofi ($SNY) and Massachusetts General Hospital in Boston will collaborate on a translational medicine project for new cancer therapies. The two-year pact brings together academic and industry professional in preclinical and clinical development work. Sanofi's global oncology group is based in Cambridge, MA. Release

> The 2012 Fierce 15 biotech Foundation Medicine has signed on Eisai to one of its multi-year collaborations on selecting cancer patients for drug studies. This is the latest in a series of pacts with drug developers. Release

> The Danish biotech Veloxis Pharmaceuticals has inked a $47.7 million distribution pact with Italy's Chiesi. Story

Pharma News

@FiercePharma: Scotland rejects Avastin for ovarian cancer. Roche says the Scots need a cancer-drugs fund like England's. Report | Follow @FiercePharma

> J&J eyes new Doxil process to reverse shortage. Story

> Roche: Scotland needs funding for rejected cancer meds. Article

> Merck plots HQ move to former Schering site. More

Medical Device News

 @FierceMedDev: AngioDynamics has agreed to purchase Vortex Medical for $55M. News | Follow @FierceMedDev

 @MarkHFierce: Stem cells derived from skin to be tested in humans as eye disease treatment--via Bloomberg. Article | Follow @MarkHFierce

 @DamianFierce: Boston Scientific will pay up to $265M for Rhythmia Medical. News | Follow @DamianFierce

> Edwards plunges on the Street as sales come up short. News

> Accutron recalls flowmeters over gas risk. Item

Pharma Manufacturing News

> Compounder tied to meningitis deaths sold large quantities. News

> Sanofi Pasteur reports more issues with vaccine quality. Story

> Mold found in Hospira dextrose solution. Report

Biotech Research News

> Japanese scientists weld stem cells to create eggs and then baby mice. More

> RXi gains SBIR grant to pursue RNAi eye cancer drug. News

> Athersys stem cell therapy displays power as MS treatment. Article

> Inovio preclinical results prove skin delivery potency for DNA vaccines. Story

And Finally… A new study indicates that lycopene, an antioxidant found in tomatoes, is associated with a significantly lower risk of stroke among men. The study tracked more than 1,000 Finnish men for more than 12 years. Story


Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.